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Background: Vascular endothelial growth factor (VEGF) plays an important role in ocular physiology. Anti-VEGF
agents are now used for treatment of common retinal diseases. This study characterises the vasoactive properties of
VEGF in isolated perfused pig retinal arterioles under normal tone or endothelin-1 (ET-1) pre-contracted conditions
and determines the influence of an anti VEGF agent on VEGF induced vasoactivity.
Methods: An isolated perfused retinal arteriole preparation was used. The outer diameter of retinal vessels was
monitored at 2 second intervals in response to VEGF and the anti VEGF agent, bevacizumab. The effect of
intraluminal delivery of VEGF was determined over a wide concentration range (10-16 to 10-7 M) both with and
without pre-contraction with ET-1 (3 x 10-9 M). Bevacizumab (0.35 mg mL-1) was applied extraluminally to
determine the influence of bevacizumab on VEGF induced vasoactive changes on ET-1 pre-contracted vessels.
Results: In retinal arterioles with normal tone, VEGF induced a concentration dependent contraction at low
concentrations, reaching 93.5% at 10-11 M and then contraction was reduced at higher concentrations, recovering
to 98.1% at 10-7 M. VEGF produced a potent concentration dependent vasodilatation in arterioles pre-contracted
with ET-1. VEGF induced vasodilatation in arterioles pre-contracted with ET-1 was significantly inhibited by
bevacizumab.
Conclusions: VEGF induced vasoactive changes in pig retinal arterioles are dependent on concentration and
vascular tone. Bevacizumab inhibits VEGF-induced vasodilatation in pre-contracted arterioles.Background
Vascular endothelial growth factor (VEGF) is a protein
with a high specificity for endothelial cells. In addition to
its role in angiogenesis, VEGF also serves multiple import-
ant functions including pro-angiogenesis [1], enhance-
ment of vascular permeability [2], changing vascular tone
[3-7], and promotion of cell survival [8], division [9], and
differentiation [10].
Neovascular ocular diseases represent a major cause of
vision loss in diseases such as proliferative diabetic retin-
opathy, age-related macular degeneration, retinopathy of
prematurity and retinal vascular occlusions [11]. Ele-
vated VEGF has been found in these diseases [12,13].* Correspondence: dyyu@cyllene.uwa.edu.au
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reproduction in any medium, provided the orVEGF has been considered to be an important patho-
genic factor as well as a therapeutic target in ocular neo-
vascularisations and associated changes [14]. Given the
introduction of therapeutic interventions using VEGF
antibodies, VEGF antagonists and VEGF receptor
antagonists in clinical ophthalmology, it is more import-
ant than ever to understand the normal functions served
by VEGF and to understand the consequences of short-
and long-term intervention with VEGF inhibitors.
It is critical to address the vasoactive properties of
VEGF and anti VEGF agents in retinal vessels, particu-
larly in cases of ischemic ocular diseases. However, little
quantitative information is available about the vasoactive
properties of VEGF at the retinal arteriole level.
The question addressed in this study is whether VEGF
induces direct effects on retinal arterioles and whether it
can be influenced by anti-VEGF agents. Our hypotheses
are that VEGF can induce concentration dependentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulated by anti VEGF agents. In the present study we
investigate the vasoactive properties of VEGF in an iso-
lated perfused porcine retinal arteriole preparation. Por-
cine retinal arteries have been shown to exhibit similar
vasoactive properties to human retinal arteries with a
range of vasoactive agents [15,16].
Methods
Isolated perfused retinal arteriole
Pig eyes were obtained from a local abattoir and picked
up by our technician. Following enucleation, the eyes
were placed in a sealed bottle of oxygenated Krebs solu-
tion and kept on ice during transfer to the laboratory
(~60 minutes). All procedures conformed to the EU Dir-
ective 2010/63/EU for animal experiments. The dissec-
tion, cannulation, perfusion, monitoring and vessel
diameter measuring system are fully described in our
previous publications using isolated perfused retinal
arterioles [15,17-19] and will be only briefly described
here.
Dissection and cannulation of vessels
The eyes were sectioned at pars plana ciliaris, separating
the anterior segment and adherent vitreous body from
the posterior pole with the aid of a dissecting micro-
scope. The retina, choroid and sclera were divided into
quadrants. The retina was then separated from the
underlying choroid and sclera. A quadrant of retina was
then placed on a hollowed glass slide containing Krebs
solution. An individual first-order retinal arteriole was
dissected free of retinal tissue with a micropipette. Typ-
ically, two arterioles were harvested from each eye. A
segment of retinal arteriole (~ 100 μm outer diameter)
about 800–1500 μm long and containing only one rela-
tively large side branch was selected. This arterial seg-
ment was then relocated to an incubation chamber
(PDMI-2, Medical System Corp, New York, USA)
mounted on the stage of an inverted microscope (Nikon
Diaphot-TMD, Japan). The chamber contained 5 mL
Krebs solution. Temperature was maintained at 37°C
and the incubating solution equilibrated with 95 % O2,
5 % CO2 so as to maintain PO2, PCO2 and pH of the
incubating solution.
The arterial segment was then cannulated at both ends
using the customized pipette and manipulating system
shown schematically in Figure 1. The vessel was then
perfused through the proximal end in the orthograde
direction at a constant flow of 5 μl min-1. The distal end
was perfused at 0.3 μl min-1 in the retrograde direction
to avoid drug entrapment. Both flows exited through the
side branch. The vessel was visualized on a video moni-
tor and a pre-programmed computer algorithm was
used to measure the external vessel diameter at userselected locations from a frame grabbed image at two
second intervals. The vessel was left to stabilize for
30 minutes prior to any drug study. A fresh arteriole was
used for each experiment.
Intraluminal and extraluminal drug delivery
Intraluminal drug delivery was administered as a 5 μl
bolus into the perfusate stream via an HPLC type sam-
ple injector valve. This system allowed the bolus to enter
the perfusate stream without pressure artefacts. A switch
on the HPLC valve signalled the time of injection of the
bolus to the computer and chart recorder. The size, and
hence the duration of the bolus, was sufficient for vaso-
active responses of the vessel to stabilise. Extraluminal
drug delivery was accomplished by direct pipetting into
the incubating solution to achieve the required concen-
tration without washing out the bath. The concentration
range used of VEGF was 10-16- 10-7 M for intraluminal
delivery. This range covers the concentration range used
for VEGF vasoactivity studies in other organs
[3,5,6,20,21]. The high cost of VEGF prohibited high
concentration levels of VEGF in the relatively large vol-
ume of the incubation bath, so only intraluminal VEGF
was tested. In a set of preliminary experiments there was
no statistically significant difference in VEGF induced
vasoactivity in porcine retinal arterioles between intra-
luminal and extraluminal application (unpublished data).
To mimic vitreous injection, bevacizumab was applied
extraluminally. All data is presented as normalised vessel
diameter percentage, where the data is normalised to the
diameter of the vessel prior to any drug administration.
Solutions and agents
Vessels were usually bathed and perfused with normal
Krebs solution of composition (in mM) NaCl 119; KCl
4.6; CaCl2 1.5; MgCl2 1.2; NaHCO3 15; NaH2PO4 1.2;
Glucose 6. All chemicals and vasoactive agents used were
obtained from Sigma Chemicals (St Louis, MO) except
recombinant human VEGF which was purchased from
Invitrogen, CA and Bevacizumab (Avastin; F. Hoffmann-
La Roche, Ltd., Basel, Switzerland) prepared by the Phar-
macy Department, Sir Charles Gairdner Hospital, Perth,
Australia. The VEGF was dissolved in Na+-Krebs solu-
tion. Stock solutions were stored at -70oC and fresh dilu-
tions were made daily.
Experiment protocol
After equilibration, an intraluminal injection of 124 mM
K+ Krebs was given to confirm retinal vessel viability.
Vessels were rejected if the contraction response did not
result in a diameter of less than 85% of the uncontracted
baseline diameter.
The effect of a wide range of intraluminal VEGF con-
centrations (10-16 to 10-7 M) was determined in
Figure 1 Schematic representation of the isolated perfused vessel system. The isolated pig retinal arteriole is cannulated at both ends and
perfused intraluminally whilst maintained in a temperature controlled bath on the stage of an inverted microscope. VEGF can be administered
intraluminally via an HPLC valve. ET-1 and bevacizumab are delivered extraluminally by addition to the bathing solution. Vessel diameter is
monitored every two seconds by an automated frame grabbing and vessel diameter measurement routine.
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contracted with extraluminal ET-1. When extraluminal
application of ET-1 (3 x 10-9M) was used to pre-contract
the vessels, the ET-1 remained in the bath during all
subsequent drug administrations. Pre-contracted vessels
can be sustained over the experimental period
[19,22,23].
Bevacizumab (0.35 mg mL-1) was applied extralumin-
ally after administering extraluminal ET-1 which
remained in the bath. This concentration of bevacizu-
mab is comparable to that used clinically [24,25].
Statistics
All statistical testing was performed using the statistics
program SigmaStat (Jandel Scientific Software, San
Raphael, CA, USA). The significance of any drug
induced concentration dependent changes was tested
using one way ANOVA, with significance acceptance
level of p< 0.05 for the F value. When comparing con-
centration response curves, the two way ANOVA using
drug concentration as the second factor was used with
an acceptance level of P< 0.05. When appropriate, Stu-
dent’s t test was employed. All mean data is expressed as
mean + standard error, and all error bars on graphs are
also standard errors. The n number refers to the number
of arterioles.
Results
The mean baseline diameter of the porcine retinal arter-
ioles prior to any drug administration was 106.4 + 1.4
μm (n= 69). VEGF induced changes in the vessel diam-
eter were not mono-phasic. A wide range of VEFG con-
centrations (10-16 to 10-7 M) was administrated to cover
this complex change. Average normalised vessel diam-
eter following intraluminal delivery of a range of VEGF
concentrations is shown in Figure 2. VEGF produced a
significant concentration dependent changes in vessel
diameter (p< 0.001). Vessel contraction was maximal at
10-11 M VEGF, reaching 93.5 + 1.5 % (n = 24). Withhigher concentrations, VEGF produced contraction was
reduced, reaching only 98.1 + 1.6% at 10-7 M.
However, VEGF induced vasoactivity was altered in
prevailing experimental condition. In pre-contracted ret-
inal arterioles, VEGF induced mono-phasic vessel dilata-
tion. ET-1 (3 x 10-9 M) was administrated extraluminally,
producing an average vessel contraction to 69.9 + 1.7 %.
Figure 3 shows the mean normalised diameter change
with intraluminal delivery of increasing concentrations
of VEGF in ET-1 pre-contracted retinal arterioles.
VEGF produced a significant concentration dependent
dilatation (p< 0.001). There was a significant dilatation
at 10-12 M and above when compared with ET-1 pre-
contraction alone. The average vessel diameter reached
96.5 + 2.7 % (n = 16) at 10-7 M.
To determine whether bevacizumab can inhibit VEGF
induced vasodilatation, a clinical concentration of beva-
cizumab used for vitreous injection was added extralum-
inally before VEGF application in ET-1 pre-contracted
vessels. Figure 4 shows the mean normalised diameter
change with intraluminal delivery of increasing concen-
trations of VEGF and extraluminal application of both
ET-1 (3 x 10-9 M) and bevacizumab (0.35 mg mL-1). ET-
1 administration produced an average vessel contraction
to 64.8 + 1.9 % (n = 19) which was not statistically differ-
ent than that found previously. Adding bevacizumab
into the bath did not produce a significant change in
vessel diameter (65.4 + 1.9 %, p = 0.815). With the pres-
ence of bevacizumab in the bath, VEGF still produced a
concentration dependent dilatation (p< 0.001) in ET-1
pre contracted vessels. The averaged vessel diameter was
significantly increased at 10-12 M and above when com-
pared with that before administration of VEGF. How-
ever, the average increase in diameter with VEGF
administration was significantly less than that without
the addition of bevacizumab (p = 0.002), reaching only
77.7 + 1.4 % at 10-7 M. Bevacizumab therefore inhibits
VEGF induced vasodilatation responses in pre-
contracted vessels.
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Figure 2 Concentration response curve of VEGF in retinal arterioles with normal tone. With intraluminal delivery over a concentration
range (10-16 – 10-7 M) the level of contraction reduced at higher VEGF concentration, producing a significant dilatation when compared to the
maximally contracted state at 10-11 M VEGF. * Denotes a significant contraction compared to initial baseline (p< 0.05).
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This study provides detailed information regarding
VEGF induced direct vasoactive changes in both normal
tone and pre-contracted retinal arterioles and demon-
strates that VEGF exhibits vasoactive effects on porcine
retinal arterioles. It has been strongly evidenced that the
vasoactive properties induced by VEGF in retinal arter-
ioles are clearly depend on the concentration and vessel
conditions before the application of VEGF. The results
also show that bevacizumab can inhibit the VEGF
induced vasodilatations in pre contracted retinal arter-
ioles. These results may be important not only to illu-
minate and interpret some consequences from patients
treated by anti VEGF agents, but also to provide some
possible clues as to how to avoid some side effects.
Anti-VEGF agents have been extensively used in ocu-
lar diseases in order to inhibit retinal neovascularisation
[13,14,26-28].
In considering therapeutic benefits and side effects of
VEGF, it is important to bear in mind that VEGF has
multiple physiological and pathological roles, and mul-
tiple factors could be influenced after modulation of
VEGF activity at the systemic or individual organ level.
In ocular neovascularisation and ischemic diseases, we
need to consider changes in angiogenesis and permeabil-
ity, and also blood flow. It has been reported thatintravitreal ranibizumab could induce retinal circulation
disturbances in patients with neovascular age-related
macular degeneration [27], neovascular glaucoma [29],
retinal vein occlusion [30], and diabetic retinopathy [31].
It is important to determine VEGF induced vasoactivity
on retinal arterioles before addressing the possible
effects of vitreal bevacizumab injection on the retinal
circulation. Our results obtained from retinal arteriole
are remarkably different than that from previous reports
in other organs. Our results show that the vasoactive
properties induced by VEGF in vessels without pre-
contraction appear to be mildly contractile at low con-
centrations (~5% reduction in the vessel diameter) and
less contractile at higher concentrations of VEGF (al-
most reaching the original diameter). However, the
results obtained from other organs show dilatation
responses of arteries, for example coronary arteries
[3,4], placental lobule [32], uterine arteries [20], and
pulmonary arteries [21]. One possible explanation is a
difference in vasoactive properties between the retinal
arteriole and peripheral vessels that were used in most
of the previous studies. Retinal blood vessels are not
innervated [33-37]. Retinal arteriole tone is mainly
regulated by local factors. The mediators derived from
the endothelial cells and retinal tissue can be consid-
ered as local regulators in addition to physical and
[VEGF] (Log M)





























Figure 3 Concentration response curve of VEGF from ET-1 pre-contracted retinal arterioles. In isolated pig retinal arterioles pre-contracted
with ET-1 (3 x 10-9 M) VEGF exhibited a concentration dependent vasodilatation response. * Denotes a significant dilatation compared to
contracted baseline (p< 0.05).
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concentration levels in most previous studies are simi-
lar to that in our study indicating that vasoactive effect
starts at concentrations as low as ~10-12 M [3,6,20,21].
To our knowledge, the effect of VEGF in pre-
contracted vessels has not previously been studied. Our
results demonstrate that in ET-1 pre-contracted vessels,
VEGF induced a potent concentration dependent vaso-
dilatation response which was inhibited by bevacizumab
at a similar concentration to that used clinically. The ra-
tionale of studying the effect of VEGF on pre-contracted
vessels is that the majority of patients treated by bevaci-
zumab are aged, and may have cardiovascular disease
and increased vessel tone. Furthermore, VEGF levels in
most ocular neovascular diseases are increased. Bevaci-
zumab is a full-length, humanized monoclonal antibody
directed against all the biologically active isoforms of
vascular endothelial growth factor (VEGF-A). It could be
expected that bevacizumab may modulate the retinal
vessel tone. Our results demonstrated that bevacizumab
can inhibit VEGF induced vasodilatation if the vessel is
pre-contracted. Retinal ischemia in some patients may
therefore be exacerbated by VEGF inhibition.
Since 2005 the experience with bevacizumab and other
anti VEGF agents in ophthalmology has accumulated
rapidly. Therapeutic benefits in neovascular oculardiseases have been demonstrated. However, despite the
excitement, a number of critical issues have been raised.
Two major issues need to be urgently addressed. Firstly,
regrowth of new vessels is often found and permanent
regression of neovascularization is rare, requiring mul-
tiple injections of anti VEGF agent. Secondly, associated
ischemia after application of anti VEGF agents has been
found in various neovascular ocular diseases. These
issues may be interlinked. Neovascularisation in the eye
and other organs occurs by both vasculogenesis and
angiogenesis. It is now known that vasculogenesis occurs
in the adult as endothelial precursor cells derived from
the bone marrow enter the circulation in response to is-
chemic injury. In addition, hypoxia regulated factors are
the key mediators of endothelial precursor cells and resi-
dent endothelial cells [11]. Ideal treatments of neovascu-
lar ocular diseases should not only target reduced
neovascularisation and vascular permeability, but also
relieve the retinal ischemia/hypoxia if possible. The ret-
ina is a functionally active tissue, with arguably the high-
est oxygen demand tissue per weight, yet the retina has
a very limited blood supply from the retinal circulation
[40-44]. Recently, reduced retinal perfusion has been
demonstrated following anti VEGF treatment in eyes
with branch retinal vein occlusion [45]. Anti VEGF
treatment further reduces retinal perfusion causing more
[VEGF] (Log M)
























ET-1 3 x 10-9 M
** * * * *
BEVACUZIMAB 0.35 mg/mL
Figure 4 Concentration response curve of VEGF from ET-1 pre-contracted retinal arterioles with extraluminal bevacizumab. In isolated
pig retinal arterioles pre-contracted with ET-1 (3 x 10-9 M) VEGF induced a concentration dependent vasodilation response was significantly
inhibited by bevacizumab. For ease of comparison the data showing the VEGF induced dilatation in the absence of bevacizumab is also included
(grey symbols). * Denotes a significant dilatation compared to contracted baseline (p< 0.05).
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regrowth of new vessels. The potential long-term effects
of anti VEGF induced vasoconstriction may need to be
considered.
An important question needing to be addressed is how
to avoid the associated ischemic retinal and choriocapil-
laris changes after intraocular administration of anti
VEGF agents [27,29-31]. Our results show that bevacizu-
mab is able to inhibit VEGF induced potent vasodilata-
tion. It is possible that the anti-VEGF agent,
bevacizumab may inhibit the vasodilatation by VEGF
after vitreous injection. As a consequence, retinal blood
flow could be reduced. Our results also show that VEGF
induced vasodilatation only occurs in ET-1 pre
contracted vessels. It could be assumed that in the cases
in these clinical reports, VEGF may act as a vasodilator
that counterbalances contractile vessel effects caused by
the original disease before anti-VEGF injection. How-
ever, anti-VEGF agent could inhibit VEGF induced vaso-
dilatation, and as consequence, vasoconstriction could
be present. It is well known that VEGF has several fam-
ily groups but it is the VEGF-A family that is principally
involved in the regulation of vasoactive tone. VEGF-A
has at least seven splice variants [46]. It could befavourable if an anti-VEGF agent could be chosen that is
not involved in the regulation of vasoactive tone, or bet-
ter still, one that can potentially improve retinal blood
flow. The design of a new anti VEGF agent should also
consider the differences of vasoactive properties between
the retinal vasculature and that in other organs, as well
as between normal tone and pre-contracted vessels. In
addition, the concentration of anti-VEGF agent also
needs to be considered, and case selection may be im-
portant. Some cases in which ischemia is predicted, such
as ischemic central retinal vein occlusion, added caution
in the use of anti-VEGF treatment may be warranted in
order to avoid exacerbating retinal ischemia.
There are undoubtedly complex mechanisms regulat-
ing ocular and serum levels of VEGF in health and dis-
ease. The increasing use of anti-VEGF drugs to treat
retinal and choroidal neovascularisation, should be ac-
companied by further studies of VEGF induced changes
in vascular tone in order maximise the therapeutic bene-
fits and to minimise unwanted side effects.
Conclusions
Using an isolated porcine retinal arteriole preparation
we have demonstrated that VEGF causes variable dose
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http://www.biomedcentral.com/1471-2415/12/10dependent effects on arterioles with normal tone, but a
potent vasodilatation in arterioles pre-contracted with
endothelin-1. The VEGF dilatation effects are signifi-
cantly counteracted by the anti-VEGF agent bevacizu-
mab. Given the widespread expression of VEGF in
tissues and the importance of VEGF for neural cells as
well as the endothelium, future detailed studies on bio-
logical parameters will be required to elucidate more
completely the role of VEGF in the eye.
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